NCT02349425View on ClinicalTrials.gov

A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 9, 2015

Primary Completion Date

February 1, 2016

Study Completion Date

February 9, 2016

Conditions
Refractory Chronic Cough
Interventions
DRUG

Gefapixant

Gefapixant 7.5 and 50mg tablets administered orally

DRUG

Placebo (for gefapixant)

Placebo to gefapixant 7.5 and 50mg tablets administered orally

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02349425 - A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) | Biotech Hunter | Biotech Hunter